Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christie M Ballantyne

Showing results (1-10 of 996) with videos related to

Pageof 100
Sort By:
Critical Pathways in Cardiology|August 2, 2007
Increasing prevalence of obesity and clustered cardiometabolic risk: can treatment of the underlying cause reverse the trends?Christie M Ballantyne
The American Journal of Cardiology|September 2, 2003
Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safetyChristie M Ballantyne
Clinical Cornerstone|October 20, 2007
Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factorsChristie M Ballantyne
The American Journal of Cardiology|November 18, 2005
Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reductionChristie M Ballantyne
Postgraduate Medicine|August 12, 2009
Strategies for optimizing lipid managementChristie M Ballantyne
JACC. Heart Failure|January 8, 2016
Lipoprotein(a) and Heart Failure: Another Reason to Study Interventions in Patients With Very High Levels of Lipoprotein(a)?Christie M Ballantyne
Current Atherosclerosis Reports|December 10, 2003
Role of selective cholesterol absorption inhibition in the management of dyslipidemiaChristie M Ballantyne
Lancet (London, England)|February 21, 2002
Soluble adhesion molecules and coronary heart diseaseChristie M Ballantyne
Postgraduate Medicine|August 12, 2009
New treatment strategies for high-risk dyslipidemic patients. IntroductionChristie M Ballantyne
Transactions of the American Clinical and Climatological Association|July 18, 2020
PRECISION MEDICINE FOR CARDIOVASCULAR DISEASE PREVENTION: WHERE DO WE STAND IN 2019 WITH A FOCUS ON INFLAMMATION AND LIPIDS?Christie M Ballantyne
Pageof 100

Showing results (1-10 of 996) with videos related to

Sort By:
Pageof 100
Critical Pathways in Cardiology|August 2, 2007
Increasing prevalence of obesity and clustered cardiometabolic risk: can treatment of the underlying cause reverse the trends?Christie M Ballantyne
The American Journal of Cardiology|September 2, 2003
Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safetyChristie M Ballantyne
Clinical Cornerstone|October 20, 2007
Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factorsChristie M Ballantyne
The American Journal of Cardiology|November 18, 2005
Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reductionChristie M Ballantyne
Postgraduate Medicine|August 12, 2009
Strategies for optimizing lipid managementChristie M Ballantyne
JACC. Heart Failure|January 8, 2016
Lipoprotein(a) and Heart Failure: Another Reason to Study Interventions in Patients With Very High Levels of Lipoprotein(a)?Christie M Ballantyne
Current Atherosclerosis Reports|December 10, 2003
Role of selective cholesterol absorption inhibition in the management of dyslipidemiaChristie M Ballantyne
Lancet (London, England)|February 21, 2002
Soluble adhesion molecules and coronary heart diseaseChristie M Ballantyne
Postgraduate Medicine|August 12, 2009
New treatment strategies for high-risk dyslipidemic patients. IntroductionChristie M Ballantyne
Transactions of the American Clinical and Climatological Association|July 18, 2020
PRECISION MEDICINE FOR CARDIOVASCULAR DISEASE PREVENTION: WHERE DO WE STAND IN 2019 WITH A FOCUS ON INFLAMMATION AND LIPIDS?Christie M Ballantyne
Pageof 100